Topline Hims & Hers Health inventory climbed as a lot as 11% Monday, persevering with a week-long rally after the FDA introduced a gathering to talk about easing peptide regulation—a push repeatedly championed by Robert F. Kennedy Jr. (Photo by Alex Wong/Getty Images) Getty Images Key Facts Hims & Hers inventory is up as a…
Eli Lilly LLY stays a dominant participant within the international weight problems market, with a lot of its latest development pushed by itsblockbuster tirzepatide (GLP-1) injections, Mounjaro for kind II diabetes (T2D) and Zepbound for weight problems. Despite being in the marketplace for simply over three years, each merchandise have delivered distinctive gross sales development…
Pfizer (NYSE: PFE) traders obtained some very dangerous information when the corporate was compelled to desert its internally developed GLP-1 weight reduction drug in April, 2025. With patent expirations on the horizon, falling even additional behind opponents like Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in an rising new drug area of interest…